SI1603941T1 - Inhibitorji zunajceliäśnega hsp90 - Google Patents
Inhibitorji zunajceliäśnega hsp90Info
- Publication number
- SI1603941T1 SI1603941T1 SI200431636T SI200431636T SI1603941T1 SI 1603941 T1 SI1603941 T1 SI 1603941T1 SI 200431636 T SI200431636 T SI 200431636T SI 200431636 T SI200431636 T SI 200431636T SI 1603941 T1 SI1603941 T1 SI 1603941T1
- Authority
- SI
- Slovenia
- Prior art keywords
- extracellular hsp90
- inhibitors
- extracellular
- hsp90
- invasiveness
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 101100016370 Danio rerio hsp90a.1 gene Proteins 0.000 title 1
- 101100285708 Dictyostelium discoideum hspD gene Proteins 0.000 title 1
- 101100071627 Schizosaccharomyces pombe (strain 972 / ATCC 24843) swo1 gene Proteins 0.000 title 1
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 abstract 3
- 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000009545 invasion Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001394 metastastic effect Effects 0.000 abstract 1
- 206010061289 metastatic neoplasm Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5029—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell motility
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Analytical Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Physiology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45481303P | 2003-03-12 | 2003-03-12 | |
| EP03015115A EP1457499A1 (en) | 2003-03-12 | 2003-07-03 | Inhibitors of extracellular Hsp90 |
| EP04718644A EP1603941B1 (en) | 2003-03-12 | 2004-03-09 | Inhibitors of extracellular hsp90 |
| PCT/EP2004/002422 WO2004081037A1 (en) | 2003-03-12 | 2004-03-09 | Inhibitors of extracellular hsp90 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI1603941T1 true SI1603941T1 (sl) | 2011-05-31 |
Family
ID=32772103
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200431636T SI1603941T1 (sl) | 2003-03-12 | 2004-03-09 | Inhibitorji zunajceliäśnega hsp90 |
Country Status (13)
| Country | Link |
|---|---|
| EP (2) | EP1457499A1 (sl) |
| JP (1) | JP4971788B2 (sl) |
| CN (1) | CN1860132A (sl) |
| AT (1) | ATE494302T1 (sl) |
| CA (1) | CA2518944C (sl) |
| CY (1) | CY1111365T1 (sl) |
| DE (1) | DE602004030890D1 (sl) |
| DK (1) | DK1603941T3 (sl) |
| ES (1) | ES2359240T3 (sl) |
| PL (1) | PL1603941T3 (sl) |
| PT (1) | PT1603941E (sl) |
| SI (1) | SI1603941T1 (sl) |
| WO (1) | WO2004081037A1 (sl) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7763769B2 (en) | 2001-02-16 | 2010-07-27 | Kci Licensing, Inc. | Biocompatible wound dressing |
| US7700819B2 (en) | 2001-02-16 | 2010-04-20 | Kci Licensing, Inc. | Biocompatible wound dressing |
| US7959915B2 (en) * | 2003-03-12 | 2011-06-14 | Tufts University | Inhibitors of extracellular Hsp90 |
| US9120774B2 (en) | 2004-11-03 | 2015-09-01 | University Of Kansas | Novobiocin analogues having modified sugar moieties |
| US7608594B2 (en) * | 2004-11-03 | 2009-10-27 | University Of Kansas | Novobiocin analogues as anticancer agents |
| EP1817295B1 (en) | 2004-11-18 | 2012-11-07 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| CA2618628C (en) | 2005-08-18 | 2014-11-18 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| WO2008079914A1 (en) * | 2006-12-21 | 2008-07-03 | Novartis Ag | Antibody quantitation |
| US20100111943A1 (en) * | 2007-03-22 | 2010-05-06 | Medical College Of Georgia Research Institute, Inc | Compositions and methods for inhibiting cancer metastasis |
| EA019156B1 (ru) | 2008-02-01 | 2014-01-30 | Такеда Фармасьютикал Компани Лимитед | Производные оксима в качестве ингибиторов hsp90 |
| WO2010001989A1 (ja) * | 2008-07-03 | 2010-01-07 | 協和発酵キリン株式会社 | 癌幹細胞及び／または癌前駆細胞の減少剤並びに癌の再発及び／または転移の予防剤 |
| US9090678B2 (en) * | 2008-08-18 | 2015-07-28 | Mesoblast, Inc. | Monoclonal antibody STRO-4 |
| CN101942017B (zh) | 2009-07-07 | 2013-08-14 | 清华大学 | 一种新的肿瘤标志物 |
| CN103694332B (zh) * | 2009-07-07 | 2017-07-11 | 清华大学 | 一种新的肿瘤标志物 |
| EP2560640A1 (en) | 2010-04-19 | 2013-02-27 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor |
| US20140294725A1 (en) | 2011-07-08 | 2014-10-02 | Sloan-Kettering Institute For Cancer Research | Uses of labeled hsp90 inhibitors |
| AU2012332424A1 (en) | 2011-11-02 | 2014-06-05 | Synta Pharmaceuticals Corp. | Combination therapy of Hsp90 inhibitors with platinum-containing agents |
| CA2853799A1 (en) | 2011-11-02 | 2013-05-10 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors |
| WO2013074594A1 (en) | 2011-11-14 | 2013-05-23 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors with braf inhibitors |
| CN105652011B (zh) * | 2014-11-20 | 2017-09-22 | 深圳市安群生物工程有限公司 | 检测人HSP90α‑2蛋白的荧光免疫层析试纸及其制备方法 |
| CN111197057B (zh) * | 2018-11-19 | 2024-04-19 | 中国科学院分子细胞科学卓越创新中心 | 调控免疫细胞迁移的组合物和方法 |
| US20220010008A1 (en) * | 2018-12-12 | 2022-01-13 | Shanghai Pharmaexplorer Co., Ltd. | Anti-human interleukin 5(il-5) monoclonal antibody and use thereof |
| CN109568311A (zh) * | 2018-12-13 | 2019-04-05 | 中国人民解放军总医院 | 坦螺旋霉素在制备抗菌消炎药物中的应用 |
| CN110511277B (zh) * | 2019-09-11 | 2022-07-26 | 江苏莱森生物科技研究院有限公司 | 一种抗hsp90单克隆抗体及其应用 |
| CN115109757B (zh) * | 2022-05-11 | 2023-06-02 | 江南大学 | 一株分泌新生霉素单克隆抗体的杂交瘤细胞株及其应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8915019D0 (en) * | 1989-06-30 | 1989-08-23 | Matthews Ruth C | Medicaments |
| US5188964A (en) * | 1990-04-12 | 1993-02-23 | Board Of Regents, The University Of Texas System | Method and kit for the prognostication of breast cancer patient via heat shock/stress protein determination |
| JP2003523313A (ja) * | 1999-03-12 | 2003-08-05 | アメリカ合衆国 | シャペロン蛋白質の阻害方法 |
| GB0008305D0 (en) * | 2000-04-06 | 2000-05-24 | Neutec Pharma Plc | Treatment of fungal infections |
-
2003
- 2003-07-03 EP EP03015115A patent/EP1457499A1/en not_active Withdrawn
-
2004
- 2004-03-09 PT PT04718644T patent/PT1603941E/pt unknown
- 2004-03-09 CA CA2518944A patent/CA2518944C/en not_active Expired - Lifetime
- 2004-03-09 CN CNA2004800128103A patent/CN1860132A/zh active Pending
- 2004-03-09 JP JP2006504609A patent/JP4971788B2/ja not_active Expired - Lifetime
- 2004-03-09 ES ES04718644T patent/ES2359240T3/es not_active Expired - Lifetime
- 2004-03-09 WO PCT/EP2004/002422 patent/WO2004081037A1/en not_active Ceased
- 2004-03-09 DK DK04718644.0T patent/DK1603941T3/da active
- 2004-03-09 DE DE602004030890T patent/DE602004030890D1/de not_active Expired - Lifetime
- 2004-03-09 AT AT04718644T patent/ATE494302T1/de active
- 2004-03-09 EP EP04718644A patent/EP1603941B1/en not_active Expired - Lifetime
- 2004-03-09 PL PL04718644T patent/PL1603941T3/pl unknown
- 2004-03-09 SI SI200431636T patent/SI1603941T1/sl unknown
-
2011
- 2011-03-31 CY CY20111100341T patent/CY1111365T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2518944C (en) | 2013-07-30 |
| CA2518944A1 (en) | 2004-09-23 |
| PL1603941T3 (pl) | 2011-06-30 |
| ATE494302T1 (de) | 2011-01-15 |
| DE602004030890D1 (de) | 2011-02-17 |
| JP4971788B2 (ja) | 2012-07-11 |
| EP1603941A1 (en) | 2005-12-14 |
| ES2359240T3 (es) | 2011-05-19 |
| EP1457499A1 (en) | 2004-09-15 |
| DK1603941T3 (da) | 2011-04-26 |
| WO2004081037A1 (en) | 2004-09-23 |
| PT1603941E (pt) | 2011-03-31 |
| EP1603941B1 (en) | 2011-01-05 |
| CN1860132A (zh) | 2006-11-08 |
| CY1111365T1 (el) | 2015-08-05 |
| JP2007524586A (ja) | 2007-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1111365T1 (el) | ΑΝΑΣΤΟΛΕΙΣ ΤΗΣ ΕΞΩΚΥΤΤΑΡΙΚΗΣ Hsp90 | |
| IL164599A0 (en) | Combination therapy for the treatment of cancer | |
| WO2003080582A3 (de) | Fredericamycin-derivate | |
| PL372211A1 (en) | Thiazolyl urea compounds for the treatment of cancer | |
| TW200637831A (en) | Triazole compounds that modulate Hsp90 activity | |
| GB0223040D0 (en) | Therapeutic compounds | |
| EP1638514A4 (en) | USE OF EPHA4 AND MODULATOR OR EPHA4 FOR THE DIAGNOSIS, TREATMENT AND PREVENTION OF CANCER | |
| DE50310516D1 (de) | Fredericamycin-derivate | |
| EP1365034A3 (en) | Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasia | |
| IL159887A0 (en) | Combination therapy for the treatment of cancer | |
| IL200410A0 (en) | Novel derivatives of psammaplin a, a method for their synthesis and their use for the prevention or treatment of cancer | |
| WO2004058158A3 (en) | Treatment of metastatic cancer with the b-subunit of shiga toxin | |
| WO2006088483A3 (en) | Compositions and methods for inhibiting the synthesis or expression of mmp-1 | |
| WO2004073615A3 (en) | Deazaflavin compounds and methods of use thereof | |
| AU2003242512A8 (en) | Use of compounds capable of inhibiting the proteolytic processing of semaphorins for prevention, treatment, diagnosis and prognosis of an invasive disease | |
| WO2005023191A3 (en) | Rage-related methods and compositions for treating glomerular injury | |
| IL174577A0 (en) | Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions | |
| GB0215526D0 (en) | Anticancer compounds | |
| WO2005016958A3 (en) | Compounds for treating tumors | |
| WO2004112690A3 (en) | 2-aminobenzoyl derivatives | |
| WO2001047505A3 (de) | Verwendung von azolen zur prävention von hautkrebs | |
| WO2005011658A3 (en) | Chroman-derivated anti-androgens for treatment of androgen-mediated disorders | |
| AU2003212990A8 (en) | Novel compositions and methods for the identification, assessment, prevention and therapy of ovarian cancer | |
| PL1680405T3 (pl) | Pochodne bengamidu i ich zastosowanie do leczenia chorób nowotworowych | |
| WO2003014128A3 (de) | Tumorhemmende cerverbindungen |